The Precise MRD Test is an ultrasensitive whole-genome sequencing (WGS) assay that gives clinicians a deeper, more personalized understanding of their patient’s disease across the cancer care continuum.
Precise MRD was designed and analytically validated to detect ctDNA with exceptional sensitivity and specificity, validated to correspond with known disease status across solid tumor types. Built on whole-genome sequencing, Precise MRD delivers a result with the performance to detect ctDNA at levels other assays may miss and the specificity to act with confidence.1
UP TO 1,000
patient-specific variants per personalized panel via whole-genome sequencing1
1.45 PPM
limit of detection (LOD95), placing it among the most sensitive tumor-informed MRD assays available1
99.66%
clinical specificity for results you use with confidence, minimizing the risk of false positives that create unnecessary clinical anxiety1
UP TO 48%
of post-surgical MRD detections occur at ultrasensitive levels2
A trusted MRD result only creates value if it adds molecular clarity to the clinical picture.
Across prospective studies, Precise MRD ctDNA status at defined clinical timepoints has predicted pathologic response, identified patients at high risk of recurrence, and correlated with survival outcomes, establishing Precise MRD results as prognostic, not merely informational.2
Clinical and analytical validation across solid tumor types, including breast, colorectal, and renal cancers.1
Validated down to 1.45 ppm estimated Variant Allele Frequency (eVAF), maintaining reliable detection even in low-shedding tumor types where disease is hardest to find.1
Neoadjuvant
Identify non-responders, often early in their treatment course, who are at the highest risk of residual disease after surgery.3
Post-surgical and adjuvant
Identify patients with microscopic levels of tumor remaining after surgery or curative intent therapy who are at the highest risk of disease recurrence.2,4
Surveillance
Regular testing provides added assurance in disease clearance and early signals of recurrence that may warrant closer clinical attention.2,5
Metastatic
Dynamic monitoring of treatment response for metastatic disease, providing real-time insights into therapeutic effectiveness.6
The best test is the one that works in your world. Precise MRD fits the way you already practice without adding to your workload. Whether you’re ordering for the first time or integrating it into routine care, Myriad supports you at every step.
Designed for the cancer care continuum: Precise MRD supports ctDNA testing across many tumor types and stages, from neoadjuvant monitoring and post-surgical MRD assessment to surveillance and recurrence detection.
Timely results for clinical decisions: Precise MRD supports ctDNA testing across many tumor types and stages, from the baseline timepoint for your neoadjuvant monitoring and post-surgical MRD assessment to surveillance and recurrence detection.
Minimal tissue requirements: Precise MRD accepts core needle biopsies alongside FFPE tissue, requiring significantly less tissue than comparable tumor-informed assays (only 4 x 5µm slides plus 1 H&E section).
Streamlined experience: Straightforward ordering process and dedicated support for ordering, sample procurement, and results interpretation, designed to fit oncology workflows.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.
Contact Information
Myriad’s clinical evidence for MRD testing in breast cancer.
Myriad’s clinical evidence for MRD testing in colorectal cancer.
Learn how MRD testing helps detect molecular signs of cancer that may remain after treatment.
This page includes AI generated images. Any similarity or resemblance to persons, living or dead, is purely coincidental.
References:
©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, Precise MRD, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.